A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
The purpose of this study is to test any good and bad effects of a study drug called tazemetostat on participants with one of the following types of cancers - rhabdoid tumor, synovial sarcoma, INI1 tumors and epithelioid tumors.
Rhabdoid tumor, synovial sarcoma, INI1 tumors, epithelioid tumors
Must be 18 years or older. Tests and procedures including blood tests, scanning, and a routine physical will be done before you can start to study to see if you are eligible.
18 - 120
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug for as long as you are seeing clinical benefit. We will continue to follow up with participants by phone every 3 months for the rest of their lives.
Knight Clinical Trials Information Line